These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 15356030)

  • 1. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection.
    Demirbilek H; Alikasifoglu A; Gonc NE; Ozon A; Kandemir N
    Clin Endocrinol (Oxf); 2012 Jan; 76(1):126-30. PubMed ID: 21790701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
    Vurallı D; Alikaşifoğlu A; İyigün İ; Canoruç D; Ozon A; Gönç N; Kandemir N
    J Clin Res Pediatr Endocrinol; 2020 Mar; 12(1):37-44. PubMed ID: 31347350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of central precocious puberty: comparison of urinary gonadotropin excretion and gonadotropin-releasing hormone (GnRH) stimulation tests in monitoring GnRH analog therapy.
    Witchel SF; Baens-Bailon RG; Lee PA
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1353-6. PubMed ID: 8636332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR; Aceto T; Weber C; Pang S
    J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty.
    Acharya SV; Gopal RA; George J; Bandgar TR; Menon PS; Shah NS
    Pituitary; 2009; 12(4):335-8. PubMed ID: 19396631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty.
    Cook JS; Doty KL; Conn PM; Hansen JR
    J Clin Endocrinol Metab; 1992 May; 74(5):1206-9. PubMed ID: 1569169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).
    Carel JC; Lahlou N; Jaramillo O; Montauban V; Teinturier C; Colle M; Lucas C; Chaussain JL
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4111-6. PubMed ID: 12213857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
    Kunz GJ; Sherman TI; Klein KO
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs.
    Brito VN; Latronico AC; Cukier P; Teles MG; Silveira LF; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2662-9. PubMed ID: 18460564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty.
    Badaru A; Wilson DM; Bachrach LK; Fechner P; Gandrud LM; Durham E; Wintergerst K; Chi C; Klein KO; Neely EK
    J Clin Endocrinol Metab; 2006 May; 91(5):1862-7. PubMed ID: 16449344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: comparison with the gonadotropin-releasing hormone test.
    Ibáñez L; Potau N; Zampolli M; Virdis R; Gussinyé M; Carrascosa A; Saenger P; Vicens-Calvet E
    J Clin Endocrinol Metab; 1994 Jan; 78(1):30-5. PubMed ID: 7507123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptorelin depot stimulation test for central precocious puberty.
    Strich D; Kvatinsky N; Hirsch HJ; Gillis D
    J Pediatr Endocrinol Metab; 2013; 26(7-8):631-4. PubMed ID: 23425599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty.
    Neely EK; Wilson DM; Lee PA; Stene M; Hintz RL
    J Pediatr; 1995 Jul; 127(1):47-52. PubMed ID: 7608810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.